Digestive system neuroendocrine neoplasm
MONDO:0024503A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).
Also known as: alimentary part of gastrointestinal system NET, alimentary part of gastrointestinal system neuroendocrine neoplasm, alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumor, well differentiated, low or intermediate grade, alimentary part of gastrointestinal system neuroendocrine tumour, carcinoid tumor of digestive system, carcinoid tumour of digestive system, digestive system NET
1620 clinical trials for this condition and its sub-types, 52 tagged with Digestive system neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Digestive system neuroendocrine neoplasm
-
Digestive system neuroendocrine tumor, grade 1/2 66 trials · 145 incl. sub-types
10 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types Sub-types →
- Esophageal neuroendocrine tumor 1 trial · 3 incl. sub-types Sub-types →
- Gastrin-producing neuroendocrine tumor 3 trials Sub-types →
- L-cell glucagon-like peptide-producing neuroendocrine tumor 0 trials Sub-types →
- Gallbladder neuroendocrine tumor, grade 1/2 0 trials
-
Pancreatic neuroendocrine neoplasm 9 trials · 85 incl. sub-types
2 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
-
Intestinal neuroendocrine neoplasm 7 trials · 21 incl. sub-types
4 sub-types
- Small intestine neuroendocrine neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
- Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types Sub-types →
-
Gastric neuroendocrine neoplasm 3 trials · 6 incl. sub-types
2 sub-types
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Gastric small cell neuroendocrine carcinoma 0 trials
-
Liver neuroendocrine carcinoma 3 trials
2 sub-types
-
Gallbladder neuroendocrine neoplasm 0 trials
2 sub-types
-
Salivary gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
New drug cocktail aims to shrink Hard-to-Treat gut tumors
Disease control Not yet recruitingThis phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
Disease control Not yet recruitingThis phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for rare gut tumors? phase 2 trial launches
Disease control Not yet recruitingThis phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…
Phase 2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC